New combo therapy shows promise against HPV-driven head and neck cancer
Disease control
Completed
This study tested a combination of two immunotherapy drugs, PDS0101 and pembrolizumab, in 95 adults with a type of head and neck cancer linked to HPV16 that had returned or spread. The goal was to see if the combination could shrink tumors and improve survival. Participants had t…
Phase: PHASE2 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 17, 2026 09:10 UTC